In this single-centre , randomised , double-blind , placebo-controlled trial , adult patients ( aged 18 years and older ) with obstructive or non-obstructive hypertrophic cardiomyopathy were randomly assigned via computer-based system to losartan ( 100 mg per day ) or placebo for 12 months .